Navigation Links
Symposium to explore role nanoparticles may play in disease
Date:4/2/2008

BETHESDA, Md. (April 2, 2008) Two Mayo Clinic researchers who study the role nanoparticles may play in hardening of the arteries and in the formation of kidney stones, will lead a symposium on how these super-small particles may affect the bodys physiology. The symposium will take place April 8 at the Experimental Biology conference in San Diego.

Nanoparticles are a thousand times smaller than the bacteria, E. coli, but recent advances in microscopy have allowed researchers to watch them interact with cells in the body, said Virginia M. Miller and John C. Lieske of the Mayo Clinic College of Medicine. They will lead the symposium, Using nanotechnology to answer physiological questions.

One of the questions physiologists want to explore is whether nanoparticles can cause diseases such as atherosclerosis, kidney stones, gall stones and periodontal disease. Dr. Lieske is investigating how nano-sized crystals in the kidney can lead to the development of kidney stones. Dr. Miller has been studying the link between atherosclerosis (hardening of the arteries) and nanoparticles which calcify within the arteries.

A fuller audio interview with the researchers is available at www.lifelines.tv.

New technology: promise and peril?

Nanotechnology presents intriguing possibilities and some troubling unknowns. The technology is already applied in commercial products as disparate as flame resistant materials and cosmetics. In addition, the technology holds promise in the development of medications that can target precise areas of the body, such as a tumor.

Because of their size, nanoparticles may more easily gain entry to the body, where the longterm effects are unknown. Dr. Miller has found that some nanoparticles cause inflammation when injected into the blood vessels of animals, an early step in the development of atherosclerosis.

Using the latest in microscopy, Dr. Miller has begun to observe nanoparticles from atherosclerotic tissue. She hopes to determine how these particles gain access to cells and whether the interaction eventually leads to cell activation or death leading to calcification.

Kidneys stones start as tiny calcifications which later become larger and eventually develop into kidney stones. Dr. Lieske hypothesizes that the nanoparticle causes the initial calcification. Once that happens, other processes can take place that results in a kidney stone.

It is not yet known where nanoparticles that are implicated in kidney stones and atherosclerosis originate whether our bodies contain them naturally or we obtain them from the environment.

Miller said research should proceed to determine if nanoparticles are safe over the long term. We may not know some of the consequences until further down the road she said.

Dr. Miller and Dr. Lieske will moderate a program on nanotechnology at Experimental Biology. The speakers are Vitaly Vodyanoy of the University of Auburn; Robert Lee of The Ohio State University; Kevin D. Gillis of the University of Missouri-Columbia and Farooq Shiekh of the Mayo Clinic College of Medicine will present at the symposium.


'/>"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
Source:Eurekalert

Related medicine news :

1. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
2. Global Sound Conference Brings Worlds Top Sound Researchers, Technologists and Musicians to Los Angeles for Four Day Symposium
3. Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida
4. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
5. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
6. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
7. AAAS symposium to address significant effects of the male parent in reproductive success
8. Symposium on drug-resistant diseases set for annual AAAS conference
9. Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium
10. Experts Offer Global Benefits Strategies at Symposium
11. AST to Address New Concept in Organ Allocation at March 13-16 Winter Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: